David Mazzo is the President and Chief Executive Officer of Caladrius Biosciences, a clinical-stage biopharmaceutical company focused on cardiovascular.
David Mazzo is the President and Chief Executive Officer of Caladrius Biosciences, a clinical-stage biopharmaceutical company focused on cardiovascular indications and autoimmune diseases. Caladrius Biosciences sold its ownership interest in a counter-flow centrifugation system to Hitachi Chemical Advanced Therapeutics Solutions for $2.5 million in 2018.
Full founder directory · Investor directory · Company funding database · Fundraising library